Ignite Creation Date:
2024-05-05 @ 5:24 PM
Last Modification Date:
2024-10-26 @ 9:31 AM
Study NCT ID:
NCT00447759
Status:
COMPLETED
Last Update Posted:
2019-05-03
First Post:
2007-03-14
Brief Title:
The Standard Care Versus Celecoxib Outcome Trial
Sponsor:
University of Dundee
Organization:
University of Dundee
Study Overview
Official Title:
Phase 4 Study A Large Streamline Safety Study Designed to Compare the Cardiovascular Safety od Celecoxib Versus Traditional Non-selective NSAIDs
Status:
COMPLETED
Status Verified Date:
2019-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
SCOTLSSS
Brief Summary:
The Standard Care versus Celecoxib Outcome Trial SCOT is a large streamline safety study designed to compare the cardiovascular safety of celecoxib versus traditional non-selective Non Steroidal Anti-Inflammatory Drug NSAID therapyTraditional NSAIDs are associated with significant morbidity and mortality from gastrointestinal toxicity Cyclooxygenase 2 Cox-2selective agents are associated with reduced upper gastrointestinal toxicityTraditional NSAIDs and Cox-2 inhibitors may also be associated with cardiovascular and renal disorders Data from both randomised and observational studies suggest that celecoxib has similar or reduced cardiovascular toxicity when compared to traditional NSAIDs However the overall safety balance of a strategy of celecoxib therapy versus a strategy of NSAID therapy is unknown The European Medicines Evaluation Agency EMEA has requested that studies of the cardiovascular safety of celecoxib be carried out within the indicated population of Europe This study addresses these issues by comparing the cardiovascular safety of celecoxib therapy with traditional NSAID therapy in the setting of the EU healthcare system
As of May 2013 7300 patients had been randomised and had accrued an average 42 years of follow up by the end of May 2014
As of May 2013 7300 patients had been randomised and had accrued an average 42 years of follow up by the end of May 2014
Detailed Description:
Aims
The present proposal seeks to compare the cardiovascular and gastrointestinal safety and effectiveness of a strategy of initial randomisation to treatment with the selective COX-2 inhibitor celecoxib or to usual-care with their current non-selective NSAID therapy with or without cyto-protection with ulcer healing drug use in either celecoxib or usual-care limbs
Trial Design
This trial utilises the Prospective Randomised Open Blinded End point PROBE design Patients with clinically diagnosed osteoarthritis OA or rheumatoid arthritis RA 60 years of age or more who are free from established cardiovascular disease and who require chronic NSAID therapy will be identified in the setting of primary care Patients will be randomised to receive either celecoxib or to continue their previous standard NSAID therapy They will then be followed up for an average of 42 years in the setting of the local National Healthcare system The study will terminate when 277 adjudicated cardiovascular events have accrued A summary is shown in the diagram below
The present proposal seeks to compare the cardiovascular and gastrointestinal safety and effectiveness of a strategy of initial randomisation to treatment with the selective COX-2 inhibitor celecoxib or to usual-care with their current non-selective NSAID therapy with or without cyto-protection with ulcer healing drug use in either celecoxib or usual-care limbs
Trial Design
This trial utilises the Prospective Randomised Open Blinded End point PROBE design Patients with clinically diagnosed osteoarthritis OA or rheumatoid arthritis RA 60 years of age or more who are free from established cardiovascular disease and who require chronic NSAID therapy will be identified in the setting of primary care Patients will be randomised to receive either celecoxib or to continue their previous standard NSAID therapy They will then be followed up for an average of 42 years in the setting of the local National Healthcare system The study will terminate when 277 adjudicated cardiovascular events have accrued A summary is shown in the diagram below
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None